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Abstract
Cytokines are important modulators of lymphocytes, and both interleukin-21 (IL-21) and IL-6 have proposed roles in T
follicular helper (Tfh) differentiation, and directly act on B cells. Here we investigated the absence of IL-6 alone, IL-21 alone,
or the combined lack of IL-6 and IL-21 on Tfh differentiation and the development of B cell immunity in vivo. C57BL/6 or IL-
21
2/2 mice were treated with a neutralizing monoclonal antibody against IL-6 throughout the course of an acute viral
infection (lymphocytic choriomeningitis virus, LCMV). The combined absence of IL-6 and IL-21 resulted in reduced Tfh
differentiation and reduced Bcl6 protein expression. In addition, we observed that these cytokines had a large impact on
antigen-specific B cell responses. IL-6 and IL-21 collaborate in the acute T-dependent antiviral antibody response (90% loss
of circulating antiviral IgG in the absence of both cytokines). In contrast, we observed reduced germinal center formation
only in the absence of IL-21. Absence of IL-6 had no impact on germinal centers, and combined absence of both IL-21 and
IL-6 revealed no synergistic effect on germinal center B cell development. Studying CD4 T cells in vitro, we found that high
IL-21 production was not associated with high Bcl6 or CXCR5 expression. TCR stimulation of purified naı ¨ve CD4 T cells in the
presence of IL-6 also did not result in Tfh differentiation, as determined by Bcl6 or CXCR5 protein expression. Cumulatively,
our data indicates that optimal Tfh formation requires IL-21 and IL-6, and that cytokines alone are insufficient to drive Tfh
differentiation.
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Introduction
B cell immunological memory consists of long-lived memory B
cells and plasma cells, which are the basis for the function and
success of almost all human vaccines in use [1]. Memory B cells
and long-lived plasma cells are generated within germinal centers
(GCs) of secondary lymphoid organs after T-dependent interac-
tions, and the presence of CD4 T cells is essential for GC
formation [2,3]. T follicular helper (Tfh) cells are the CD4 effector
subset required to provide B cell help [4,5,6,7,8].
Tfh were originally identified through their high expression of
CXCR5 [9,10,11], a chemokine receptor normally found on B
cells, which allows these cells to migrate to the B cell follicle
[12,13,14]. These cells are distinguished from other CD4 subsets
by the upregulation of several additional surface molecules
including inducible costimulatory molecule (ICOS), CD40L, PD-
1, and BTLA [4,15,16,17,18,19]. The recent identification of Bcl6
as a master transcriptional regulator of Tfh differentiation [4,5,6]
and demonstration that Tfh were required for GC formation
[4,5,6,7] firmly established Tfh as their own distinct CD4 effector
subset.
How Tfh differentiation occurs is currently unresolved. There
are currently several proposed models of Tfh development, which
center on the cell types involved, the putative mechanisms of Bcl6
induction, and the kinetics of the process [8]. One model proposes
that direct induction of Bcl6 via cytokines is sufficient to generate
the Tfh subset [5,7]. A second model suggests that multiple
interactions, including B cells, are required for Tfh differentiation
[20]. Additional studies have been needed to test these models in
detail.
When considering factors controlling Tfh differentiation, it
must be done in the context of the knowledge that cytokines
are essential for generating many of the known CD4 T cell
subsets (Th1, Th2, Th17 and iTreg). Therefore, it is likely that
cytokines contribute to Tfh differentiation. Nevertheless, there
have been numerous conflicting findings in the literature on
this topic. The primary candidate cytokines for Tfh differen-
tiation have been IL-6 and IL-21 [5,7,21,22]. Tfh secrete high
levels of IL-21 [7,16,17,23], and work from several laboratories
has indicated that IL-21 can affect Tfh differentiation and
function [7,22]. Importantly, multiple labs have found that the
lack of either IL-21 alone [24,25,26,27] or IL-6 alone [27,28]
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context of protein immunizations or viral infections. Addition-
ally, IL-21 expression is not restricted to Tfh, as other CD4 Th
subsets can produce IL-21 [21,29,30,31,32]. IL-6 induces IL-
21 production [21,29,33]. Th17 can be differentiated in vitro
from naı ¨ve CD4 T cell cultures in the presence of IL-6 and
TGFb,o rI L - 2 1a n dT G F b,v i aaS T A T 3d e p e n d e n tp a t h w a y
[29,31]. A major potential confounding factor for delineating
the role of IL-21 in Tfh differentiation is that IL-6 also
primarily signals through STAT3 [28,34], and may compen-
sate for the lack of IL-21.
Given the varied observations regarding the role of IL-21 and
IL-6 in Tfh differentiation, we endeavored to examine the function
of these cytokines in greater detail in vitro, and in vivo by studying
mice lacking both IL-21 and IL-6. We also further characterized
the independent and cooperative nature of IL-21 and IL-6 on B
cell immunity.
Materials and Methods
Mice
C57BL/6J (B6) and IL-6
2/2 [35] mice were purchased from
Jackson Laboratory (Bar Harbor, ME). IL-21
2/2 mice were
generated as described [24] and obtained from the Zajac lab
(University of Alabama). IL-21
2/2 mice were backcrossed for
greater than 10 generations on the B6 background. Whole-
genome SNP analysis (Illumina, Golden Gate, SD), verified IL-
21
2/2 mice were .99% B6 by SNP analysis (data not shown). IL-
21
2/2, IL-6
2/2, and OTII TCR transgenic mice were bred and
maintained at the La Jolla Institute for Allergy and Immunology
under specific pathogen-free conditions. All animal experiments
were conducted on mice 6-12 weeks of age in accordance with the
American Association for Laboratory Animal Science on the care
and use of animals, and an animal study protocol (AP006-SC1-
0809) approved by the La Jolla Institute for Allergy and
Immunology Institutional Animal Care and Use Committee.
In vitro cultures
Total CD4 T cells were isolated from whole splenocytes by
negative selection using magnetic beads (Miltenyi). CD4 T cell
purity was greater than 95%. Naı ¨ve CD4 T cells were further
purified by sorting, excluding NKT cells and Tregs
(CD4
+CD44
2NK1.1
2CD25
2) on a FACSAria (BD Biosciences).
Cells were resuspended in D-10 (DMEM supplemented with 10%
fetal calf serum (FCS), 2 mM GlutaMAX (Gibco), 100 U/mL
penicillin/streptomycin (Gibco)) +10 ng/mL hIL-2+50 mM beta-
mercaptoethanol (b-ME). Some cultures also included 2 ng/mL
IL-7. Cells were stimulated in 24-well plates coated with 8 mg/
mL anti-CD3 and 8 mg/mL anti-CD28 (BioXCell). For in vitro
differentiated cultures, additional cytokines and blocking anti-
bodies were added at this time, and cells were cultured at 37uC
for 72 h: Th0 (forced neutral), 10 mg/mL anti-IFNc,a n t i - I L - 4 ,
and anti-TGFb; Th1, 10 ng/mL IL-12+10 mg/mL anti-IL-4 and
anti-TGFb; Th2, 10 ng/ml IL-4+10 mg/mL anti-IFNc and anti-
TGFb; Th17, 5 ng/ml TGFb +20 ng/ml IL-6 +10 mg/ml anti-
IFNc and anti-IL-4; Th0+IL-6, 10 ng/ml IL-6+ Th0; Th0+IL-
21, 10 ng/ml IL-21+ Th0. In some instances, naı ¨ve CD4 T cell
cultures were transferred after 24 h onto fresh anti-CD3 coated
plates. For the polarizing conditions, all neutralizing cytokine
mAbs were purchased from BioXCell, and all recombinant
cytokines, except IL-21 (R&D Systems), were purchased from
Peprotech. To block IL-21 signaling in vitro, 5 ng/mL IL-21R-
Fc (R&D Systems) or 5 mg/ml neutralizing IL-21 mAb (clone
FFA21, eBioscience) was added to Th0+IL-21 cultures; to block
IL-6 signaling in vitro, 10 mg/ml anti-IL-6 (BioXCell) was added
to Th0+IL-6 cultures. CD4 differentiation was assessed after a
total of 72 h in culture. After the initial 72 h stimulation, CD4 T
cells were transferred into new 24-well plates containing fresh D-
10+ IL-2 + b-ME and split as needed. For flow cytometry
analysis, live B220
2CD44
hiCD4
+ cells were gated. Normally
greater than 80% of stimulated CD4 T cells were CD44
hi at these
time points.
Adoptive transfers, immunizations and infections
For viral infections, mice were infected with 1610
5 plaque
forming units of LCMV Armstrong by intraperitoneal (i.p.)
injection. For in vivo antibody treatments, mice were pre-treated
with antibody 24 h prior to LCMV infection, and given several
additional doses throughout the course of the acute infection. Mice
initially received 0.5 mg neutralizing aIL-6 (clone MP5-20F3, rat
IgG1; BioXCell) or isotype mAb (anti-rat IgG1; BioXCell), and
subsequently given 0.25 mg mAb (i.v.) every other day following
the initial dose through the end of the experiment.
For primary protein responses, mice were immunized (i.p.) with
100 mg alum-precipitated NP-Ova (Sigma; Biosearch Technolo-
gies) in PBS. Briefly, NP13-Ova was dissolved in an equal volume
of PBS containing 10% KAl(SO4)2 (Sigma), and the pH was
adjusted to 6.5–7.0 with NaOH. OTII TCR transgenic CD4 T
cells were isolated by negative selection using magnetic beads
(Miltenyi), and 250,000 OTII cells were transferred intraveneously
to host recipients by retro-orbital injections.
Flow cytometry
Single cell suspensions of whole spleens were obtained by gentle
mechanical disruption and ACK lysis (Gibco). Surface staining for
flow cytometry used monoclonal antibodies to SLAM (CD150,
Biolegend), CD4, CD8, CD44, CD62L, IgD, CD45.1 (eBios-
ciences), PD-1, FAS, B220, GL7, biotinylated CD138 (BD
Pharmingen), and FITC-labeled peanut agglutinin (PNA, Vector
Laboratories). The majority of surface stains were done for 30 min
at 4uC in FACS buffer (PBS +0.5% BSA +0.1% NaN3). As
previously described [4], CXCR5 was detected using purified anti-
CXCR5 (BD Pharmingen), followed by biotinylated anti-rat IgG
(Jackson ImmunoResearch Laboratories), and PE- or APC-labeled
streptavidin (eBioscience) in FACS buffer supplemented with 2%
FCS and 2% normal mouse serum. Following surface staining,
intracellular Bcl6 was detected using a directly conjugated mAb
against human Bcl6 that cross-reacts with murine Bcl6 (clone
K112-91; BD Pharmingen) using the FOXP3 nuclear staining
protocol (eBioscience). For intracellular cytokine staining, spleno-
cytes were stimulated with 400 ng/mL PMA and 150 ng/mL
ionomycin in the presence of brefeldin A (BFA) for 4 h, followed
by surface staining. Intracellular cytokine staining was performed
with directly conjugated mAb against IFN-c, IL-4, or IL-17
(eBioscience). IL-21 was detected using an IL-21R-Fc chimeric
protein (R&D Systems) followed by PE-labeled anti-human IgG
(Jackson ImmunoResearch). Samples were acquired on an LSRII
containing DIVA software (BD Biosciences), and analyzed with
FlowJo software (Treestar, Inc).
ELISA
Anti-LCMV IgG was quantified from mouse serum by ELISA 8
days following LCMV infection as previously described [36].
LCMV cell lysate was used as the capture antigen to coat 96-well
Polysorp microtiter plates (Nunc). IL-21 was quantitated from the
supernatant of in vitro differentiated CD4 T cells. Day 7 polarized
CD4 T cells were stimulated overnight with 400 ng/mL PMA and
150 ng/mL ionomycin. 96-well Maxisorp microtiter plates (Nunc)
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(goat IgG, R&D Systems) as the capture antibody. Following the
primary incubation, samples were treated with biotinylated goat
anti-mouse IgGc (Southern Biotech) to detect anti-LCMV IgG, or
biotinylated goat anti-mouse IL-21 (R&D Systems) to detect IL-21.
Plates were subsequently incubated with HRP conjugated Avidin
D (Vector Laboratories) and visualized using OPD (o-phenylene-
diamine dihydrochloride; Sigma) substrate.
Quantitative real-time PCR
RNA was extracted with an RNeasy micro kit (Qiagen),
including Qiashredder and on-column digestion of genomic
DNA. cDNA synthesis was performed using SuperScript II
Reverse Transcriptase (Invitrogen) with random hexamer primed
reactions. Quantitative real-time PCR (qPCR) reactions were
performed in triplicate using iTaq SYBR Green Supermix with
ROX (Bio-Rad) on a Roche LightCycler 480 (Roche). Primers
were as described [4]. G6PDH was used as the reference gene for
normalization.
Statistical analysis
All statistical tests were performed using Prism 5, and p values
were calculated using two-tailed, unpaired Student t tests, with a
95% confidence interval. Error bars represent the SEM.
P,0.05= *, P,0.005= **. P,0.0005= ***.
Results
IL-21 is produced by many CD4 T effector subsets
Some activated CD4 T cells can produce high amounts of IL-21
[21,30,31,32]. IL-21 production by Th1, Th2, and Th17 polarized
CD4 T cell cultures was investigated by intracellular staining for
IL-21 protein. Splenic CD4 T cells from C57BL/6 mice were
isolated by magnetic bead negative selection, and stimulated with
aCD3 and aCD28 in the presence or absence of exogenous
cytokine and appropriate neutralizing antibodies. We observed
that CD4 T cells cultured for 7 days under Th1 polarizing
conditions co-produced high levels of IFNc and IL-21 (Figure 1A).
Under Th2 conditions CD4 T cells co-produced IL-4 and IL-21
(Figure 1B). CD4 T cells cultured under Th17 conditions co-
produced IL-17 and IL-21 (Figure 1C), as has been widely
reported [21,29,30,31]. To confirm our flow cytometry results, IL-
21 from culture supernatants was measured by ELISA, and
normalized to cell numbers. After 7 days in culture, CD4 T cells
were stimulated overnight in the presence of PMA and ionomycin.
Supernatants from CD4 T cells cultured under forced neutral
conditions (Th0) produced little IL-21 compared to CD4 T cells
cultured under Th1, Th2, and Th17 conditions (Figure 1D). Of
note, magnetic bead purified CD4 T cells stimulated with aCD3
and aCD28 alone, without blocking monoclonal antibodies
(Unbiased, U), produced large amounts of IL-21 (Figure 1D).
Collectively, we interpreted those results to mean that IL-21
Figure 1. IL-21 can be produced by Th1, Th2 or Th17 cell in vitro. (A–D) Magnetic bead purified total CD4 T cells were stimulated with plate-
bound aCD3 plus aCD28 without cytokine blocking mAbs (unbiased, U), or in the presence of aIFNc + aIL-4 (Th0), IL-12 + aIL-4 (Th1), IL-4 + aIFNc
(Th2), or IL-6/TGFb + aIFNc & aIL-4 (Th17). Day 7 CD4
+B220
2 gated in vitro cultured cells were stained by ICS after 4 h stimulation in PMA/ionomycin.
Representative dot plots of IL-21 and the respective cytokine associated with each subset, (A) IFNc (Th1), (B) IL-4 (Th2), or (C) IL-17 (Th17). (D) IL-21
was measured by ELISA from day 7 cells that had been washed, and then restimulated overnight in the presence of PMA/ionomycin. IL-21 was
normalized to cell number per well. (E) Sorted naı ¨ve CD4 T cells (CD4
+CD44
2NK1.1
2CD25
2) were cultured under unbiased (U), Th0 or Th1 conditions.
ELISA analysis of IL-21 production from day 7 cultured CD4 T cells restimulated overnight with PMA/ionomycin (normalized to cell number per well).
‘‘—’’ = no stim. Data are representative of $2 independent experiments.
doi:10.1371/journal.pone.0017739.g001
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autocrine IL-21 production by activated naı ¨ve CD4 T cells.
IL-21 production induced in naı ¨ve CD4 T cells
We then examined purified naı ¨ve T cell cultures under more
stringently controlled conditions. Naı ¨ve, FACS sorted CD4 T cells,
excluding Tregs and NKT cells, (CD44
loCD25
2NK1.1
2) did not
produce IL-21 upon TCR stimulation alone (Figure 1E), or under
neutral (Th0) conditions (Figure 1E & 2A–B). Therefore, sorted
naı ¨ve CD4 T cells were used for all subsequent experiments.
Addition of IL-6 to naı ¨ve CD4 T cell cultures (Th0 + IL6)
dramatically increased the frequency of IL-21 producing CD4 T
cells compared to Th0 cultures (44% vs. 0.5%; P=0.0002;
Figure 2A). IL-21 production was directly mediated through IL-6
signaling, as the presence of a neutralizing anti-IL-6 monoclonal
antibody (mAb) in the culture led to a large reduction in IL-21
expression levels (6%; P=0.0004).
High IL-21 expression could also be induced by the addition of
IL-21 (42% vs. 3%; Figure 2B-D) [7,21]. This effect was directly
mediated through IL-21 signaling, as the addition of soluble IL-21
receptor (IL-21R-Fc) reduced the generation of IL-21 producing
CD4 T cells in Th0 + IL-21 cultures to background levels (2%;
P,0.0002; Figure 2B-D)[21]. We also screened anti-IL-21 mAbs
for IL-21 neutralization activity and identified a clone with potent
activity. Addition of neutralizing anti-IL-21 to Th0 + IL-21
cultures completely blocked the differentiation of IL-21 producing
CD4 T cells (P=0.0002; Figure 2B–D). The addition of IL-6 or
IL-21 to naı ¨ve CD4 T cell cultures specifically induced IL-21
secretion, as IFNc production was not upregulated (Figure 2A–B).
Thus, we confirm and extend the finding that IL-21 expression is
strongly induced in CD4 T cells by IL-6 or IL-21.
High IL-21 production does not instruct Tfh
differentiation in vitro
While the addition of IL-6 or IL-21 to naı ¨ve CD4 T cell cultures
induced IL-21 expression, we wondered if these conditions
generated true Tfh cells in vitro. Tfh are defined by high CXCR5
expression and expression of the Tfh transcription factor Bcl6. Tfh
Figure 2. In vitro stimulation of purified naı ¨ve CD4 T cells with IL-6 or IL-21 drives high IL-21 expression. (A–D) Naı ¨ve sorted CD4 T cells
(CD4
+CD44
2NK1.1
2CD25
2) were stimulated for 3 days on aCD3/aCD28 coated plates in the presence of aIFNc, aIL-4, and aTGFb (Th0) 6 IL-6 or IL-
21. Reagents to block IL-21 (5 mg/ml) or IL-6 (10 mg/ml) signaling were also added at this time where indicated. IL-21R-Fc intracellular staining was
used to identify IL-21 producing cells after 4 h of PMA/ionomycin stimulation. (A) Flow cytometry analysis of IL-21 and IFNc production in day 7 Th0,
Th0 + IL-6, and Th0 + IL-6 + aIL6 polarized CD4 T cell cultures. Cells were gated on B220
2CD44
hi CD4 T cells. *** P,0.0005. (B–D) FACS analysis of IL-
21 and IFNc production in day 3 Th0 + IL-216 aIL-21 or IL-21R-Fc differentiated CD4 T cells. (B) Representative plots (B220
2CD44
hi CD4 T cells). (C)
Quantitation of IL-21 production or (D) IL-21 MFI. ** P,0.003, *** P,0.0003. Data are representative of $2 independent experiments for each
condition with duplicate samples. MFI, mean fluorescence intensity.
doi:10.1371/journal.pone.0017739.g002
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examined the role of IL-6 and IL-21 in driving Tfh development
in CD4 T cells. We first compared CXCR5 mRNA levels of sorted
naı ¨ve CD4 T cells stimulated in the presence or absence of IL-6
versus in vivo Tfh. In vivo OTII Tfh were generated by protein
immunization of C57BL/6 mice that received adoptively trans-
ferred OTII cells. There are two stages of Tfh differentiation [8].
CD4 T cells found within the germinal center (GC Tfh) are a more
polarized population of Bcl6
+CXCR5
+ Tfh CD4 T cells that
express the highest level of PD-1, SAP, and GL7 and have
enhanced B cell help capabilities [8,16,17,37]. At day 8 after NP-
Ova plus alum immunization, OTII Tfh (CXCR5
+GL7
2) and
OTII GC Tfh (CXCR5
+GL7
+) express high levels of CXCR5
mRNA (Figure 3A). CD4 T cells differentiated in the presence of
IL-6 (Th0 + IL-6) modestly upregulate CXCR5 mRNA compared
to Th0 cultures (P,0.0001; Figure 3A). However, in vitro ‘‘Th0 +
IL-6’’ cell CXCR5 mRNA levels were 20-fold lower than in vivo
Tfh (Figure 3A). We next assessed CXCR5 protein expression by
flow cytometry, and observed negligible CXCR5 protein expres-
sion by in vitro Th0 or Th0 + IL-6 cells (Figure 3B). CXCR5
expression on freshly isolated naı ¨ve (CD44
lo) or CD44
hiCXCR5
+
CD4 splenocytes is shown for comparison (Figure 3B). CXCR5
surface expression by in vitro cultured cells was also unaffected by
the addition of IL-21 (Th0 + IL-21; Figure 3C). Together, these
data indicate that IL-21 and CXCR5 expression are indepen-
dently regulated in CD4 T cells.
We next examined whether IL-21 modulates the expression of
Bcl6. Expression levels of Blimp-1 were examined in parallel, as
Blimp-1 is a potent antagonist of Bcl6 that inhibits Tfh
differentiation [4,38]. Previous studies have shown that IL-6 and
IL-21 can induce or sustain Bcl6 mRNA in CD4 T cells or B cells
[5,7,26,39]. In addition, Blimp-1 can also be induced by IL-21
[40]. As the expression of these transcription factors is intimately
tied to Tfh differentiation [4], we assessed Bcl6 and Blimp-1
mRNA expression at several early timepoints after stimulation of
naı ¨ve CD4 T cells in vitro. Th0 cultures expressed low levels of
Figure 3. High IL-21 production in CD4 T cell cultures does not instruct Tfh differentiation. Naı ¨ve sorted CD4 T cells were stimulated for
72 h on aCD3 plus aCD28 coated plates in the presence of aIFNc, aIL-4, and aTGFb (Th0) 6 IL-6 or IL-21. (A) CXCR5 mRNA expression normalized to a
housekeeping gene, G6PDH, in naı ¨ve (CD4
+CD44
lo), day 3 in vitro polarized CD4 T cell cultures (Th0 or Th0 + IL-6), or OTII CD4 T cells from day 8 NP-
OVA plus alum in vivo immunized mice (CD44
hiCXCR5
+GL7
2 Tfh or CD44
hiCXCR5
+GL7
+ GC Tfh). (B) Quantitation of CXCR5 mean fluorescence
intensity (MFI) in day 3 cultures (Th0 or Th0 + IL-6) or CD4 splenocytes (naı ¨ve, CD44
lo; CXCR5
+, CD44
hi), and histogram. (C) CXCR5 analysis in 72 h Th0
(black) or Th0 + IL-21 (red) cultures. Th0 and Th0 + IL-21 cultures stained with isotype mAb (blue). (D–E) Timecourse of Bcl6 (D) and Blimp-1 (E) mRNA
expression normalized to a housekeeping gene, G6PDH, in Th0 or Th0 + IL-6 CD4 T cell cultures. (F) FACS analysis of Bcl6 protein expression in
germinal center B cells (GL7
+B220
+) versus non GC B cells (GL7
2B220
+) in splenocytes 8 days following LCMV infection. (G) Bcl6 protein expression in
day 3 in vitro differentiated CD4 cultures (Th0 or Th0 + IL-6) versus freshly isolated naı ¨ve CD4 splenocytes (CD44
lo). Left, quantitation of Bcl6 MFI.
Right, Bcl6 histogram. (H) Bcl6 analysis in 72 h Th0 (black) or Th0 + IL-21 (red) cultures. Naı ¨ve splenocytes are stained for comparison (CD44
lo, gray).
Data are representative of $2 independent experiments with duplicate samples.
doi:10.1371/journal.pone.0017739.g003
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over the course of the experiment (Figure 3D). Addition of IL-6 to
the Th0 cultures led to a sharp increase in Bcl6 mRNA at 24 h
post-stimulation, which quickly tapered off to Th0 levels by 72 h
(Figure 3D), similar to one report [5] though different than
another report that saw no Bcl6 induction [28]. IL-6 also led to an
increase in Blimp-1 mRNA at 24 h (Figure 3E), and Blimp-1 levels
appeared to be better maintained than Bcl6 at the later timepoints
(Figure 3D–E). Blimp-1 expression after IL-6 treatment was
significant, as the 6-fold increase at 24 h and 3-fold increase at
72 h was similar to the 5-fold differences seen between in vivo
non-Tfh and naive CD4 T cells studied contemporaneously [17].
Thus, IL-6 alone does not selectively induce Bcl6 mRNA over
Blimp-1 mRNA in CD4 T cells.
Post-transcriptional regulation can strongly impact Bcl6 expres-
sion, and can result in substantial discrepancies between Bcl6
mRNA and protein expression [20,41,42]. Therefore, the ability
to assess Bcl6 protein at the single cell level was essential for a fuller
understanding of Bcl6 regulation in CD4 T cells. We established
an intracellular flow cytometry stain to detect Bcl6 protein with a
new monoclonal antibody. Bcl6 staining conditions were first
optimized by comparing naı ¨ve versus germinal center B cells
(GL7
2 vs. GL7
+; Figure 3F). We then examined Bcl6 protein
expression in 72 h CD4 T cell cultures. The addition of IL-6 did
not increase Bcl6 protein expression above basal Th0 levels
(Figure 3G). A slight increase in Bcl6 expression was observed with
the addition of IL-21 to Th0 cultures (Figure 3H). However, Bcl6
upregulation in the Th0 + IL-21 cells did not correlate with
enhanced CXCR5 surface expression. Collectively, our results
demonstrate that TCR stimulation plus IL-6 or IL-21 cytokine
alone is not enough to drive Tfh differentiation of purified naı ¨ve
CD4 T cells in vitro, as neither Bcl6 nor CXCR5 protein
expression were significantly induced.
Combined IL-6 and IL-21 deficiency in vivo
In order to investigate the roles of IL-6 and IL-21 in Tfh
differentiation and the development of B cell immunity, we utilized
a murine model. We recently reported that Tfh differentiation and
germinal center development were normal in IL-6
2/2 mice [27].
Others have shown Tfh differentiation to be relatively unaffected
in IL-21
2/2 mice [24,25,26,27]. However, different laboratories
have had different results or interpretations [7,22]. As both
cytokines signal through STAT3 [32,43], we hypothesized that
these two cytokines could have redundant, collaborative functions
in vivo.
IL-6 deficient mice have a 2–4 fold decrease in early T-
dependent virus-specific IgG responses compared to wildtype
C57BL/6 (B6) mice following acute infection with LCMV [27].
We determined that the IL-6
2/2 phenotype could be recapitu-
lated by blocking IL-6 signaling using a neutralizing IL-6 mAb.
Treatment of B6 mice with aIL-6 mAb led to a severe loss of day 8
serum LCMV-specific IgG compared with B6 mice given an
isotype control mAb (20% of wildtype level; P=0.0016;
Figure 4A). Thus, ablation of IL-6 signaling could be achieved
in B6 mice by treatment with neutralizing aIL6 mAb.
Differential role of IL-6 and IL-21 in development of B cell
immunity
Having validated the in vivo IL-6 blockade, we could test the
importance of IL-6 alone (aIL-6), IL-21 alone (IL-21
2/2), or the
combined absence of IL-6 and IL-21 (IL-21
2/2+ aIL-6) for Tfh
differentiation and the development of B cell immunity. We
examined the impact of these cytokines on the early antiviral
antibody response at day 8 after acute LCMV infection. Serum
antibody levels were quantitated by endpoint ELISA analysis
(Figure 4A). The absence of IL-21 alone (IL-21
2/2) led to a 50%
loss of LCMV specific IgG compared to B6 mice (P=0.0016)
Figure 4. Cooperation of IL-6 and IL-21 for plasma cell generation and antibody responses. C57BL/6 (B6) or IL-21
2/2 mice treated with
aIL-6 or isotype mAb throughout the acute LCMV infection. (A) Titers of anti-LCMV IgG in the serum of B6 or IL-21
2/2 mice 6 aIL-6 mAb 8 days
following LCMV infection: B6 vs. B6 + aIL-6 (**, P=0.0016), B6 vs. IL-21
2/2 (*, P=0.025), B6 vs. IL-21
2/2 + aIL-6 (**, P=0.0016), and IL-21
2/2 vs.
IL-21
2/2 + aIL-6 (**, P=0.0012). (B) Quantitation of plasma cell development by FACS: B6 vs. IL-21
2/2 (***, P=0.0008), B6 vs. IL-21
2/2 + aIL-6
(***, P,0.0001), and IL-21
2/2 6 anti-IL-6 (*, P=0.0143). (C) Plasma cell (CD138
+IgD
2) development 8 days post-infection, gated on CD19
+
splenocytes. Data are representative of 3 independent experiments; n=5–6 mice per group. ns, not significant.
doi:10.1371/journal.pone.0017739.g004
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IL-21 and IL-6 (7% of wildtype level; P=0.002; Figure 4A). At
day 8, the peak of the plasma cell response [45], we observed a
significant decrease in plasma cell (CD138
+IgD
2CD19
+) frequen-
cy by flow cytometry in IL-21
2/2 mice compared to B6 mice
(P,0.0008). Interestingly, while antibody levels were substantially
reduced in the absence of IL-6, plasma cell development was
modestly impacted (6% vs. 5%; B6 vs. B6 + aIL-6; P=0.2056).
The largest reduction in plasma cell frequency was observed in the
combined absence of both IL-6 and IL-21 (B6 vs. IL-21
2/2 + aIL-
6; P,0.0001; Figure 4B–C).
Germinal center formation is detectable at day 6 after acute
LCMV infection, with a large germinal center response present by
day 8 post-infection. The reduction in plasma cell numbers at day
8 in the absence of IL-21 is most likely a reflection of the critical
role of IL-21 in driving plasma cell differentiation from germinal
center B cells (Figure 4B–C) [25,26,46]. IL-21 is a potent STAT3-
dependent inducer of Blimp-1 [40,47,48]. Thus the combined
absence of IL-6 and IL-21 through 8 days post-infection results in
a predominantly IL-6 dependent loss of antibody production by
the extrafollicular plasma cells (IL-21
2/2 vs. IL21
2/2 + aIL-6;
P,0.0143; Figure 4B–C), and the absence of germinal center
derived plasma cells (IL-21 dependent), resulting in a near
complete abrogation of the serum antibody response to the viral
infection.
Previous studies have characterized the individual roles of IL-21
or IL-6 on B cells and found that IL-21 has a large impact on
germinal center development [25,26,35]. We examined what
effect the combined absence of both IL-21 and IL-6 would have on
germinal center formation (Figure 5). Germinal center B cell
(GL7
+Fas
+) frequencies were similar in B6 mice treated with either
aIL-6 or isotype mAb (Figure 5A–B). However, the absence of IL-
21 led to a consistent 50% loss of germinal center B cells compared
to B6 mice (P=0.0233; Figure 5A–B). As previously noted [25],
PNA staining intensity is decreased on germinal center B cells in
the absence of IL-21 (P=0.0003; Figure 5C), indicative of reduced
GC B cell proliferation. Interestingly, germinal center B cell
numbers in IL-21
2/2 mice were unaffected by the additional loss
of IL-6 (Figure 5A–B), as was PNA MFI (Figure 5C). Thus, while
IL-21 and IL-6 cooperate in stimulating plasma cell responses, IL-
21 has a unique role in enhancing germinal center B cell
proliferation, maintenance, and function.
Optimal Tfh differentiation requires IL-6 or IL-21
We next examined what effect the combined absence of IL-6
and IL-21 would have on Tfh development (Figure 6). Similar to
previous observations [24,25,26,27], we did not observe major
differences in the development of Tfh (CD44
hiCXCR5
+SLAM
lo)
in the absence of either IL-6 alone [27,28], or IL-21 alone
[24,25,26], compared to WT B6 mice (Figure 6A–B). However,
the combined absence of both IL-6 and IL-21 resulted in a 25%
loss in Tfh generation compared to wildtype mice (P=0.0016;
Figure 6A–B). We also observed a strong correlation between
reduced Tfh frequency and CXCR5 protein expression levels
within the Tfh population. No difference in CXCR5 protein
expression was observed in the absence of IL-6 alone or IL-21
alone (Figure 6C). However, reduced CXCR5 MFI was observed
in the combined absence of both IL-6 and IL-21 (B6 vs. IL-21
2/2
+ aIL-6; P,0.0001; Figure 6C). Similar to what we characterized
in GC B cells, increased Bcl6 protein expression in Tfh (CXCR5
+)
versus non-Tfh (CXCR5
2) cells can be observed by FACS
(Figure 6D). Compared to B6 controls, the absence of IL-6 (B6 +
aIL-6) had no effect on Bcl6 protein expression in the Tfh
population (Figure 6D). Although the lack of IL-21 (IL-21
2/2) did
appear to result in lower Bcl6 protein expression, this did not
reach statistical significance (P=0.073; Figure 6D). However, Bcl6
expression was significantly decreased in Tfh generated in the
absence of both IL-6 and IL-21 (P=0.0032, Figure 6D).
We also examined the development of the GC Tfh population
in the absence of IL-6, IL-21, or combined absence of both IL-6
Figure 5. IL-21, but not IL-6, is needed for optimal germinal center B cell development. (A) Germinal center B cells (GL7
+Fas
+ gated, total B
cell gate shown) in C57BL/6 (B6) or IL-21
2/2 mice treated with anti-IL-6 (aIL6) or isotype mAb. Splenocytes were analyzed 8 days following acute
LCMV infection. (B) Frequency of germinal center B cells of total B cells. *, P,0.02. (C) Quantitation of the PNA mean fluorescence intensity (MFI) in
germinal center B cells. ***, P=0.0003. Data are representative of 3 independent experiments; n=5–6 mice per group. MFI, mean fluorescence
intensity; ns, not significant.
doi:10.1371/journal.pone.0017739.g005
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hiCXCR5
+GL7
+) were observed in all
conditions, and the frequency of GC Tfh in the absence of either
IL-6 alone or IL-21 alone was similar to B6 mice (Figure 6E-F).
However, the combined absence of both IL-6 and IL-21 led to a
40% reduction in GC Tfh frequency compared to B6 mice
(P,0.003; Figure 6E–F). CXCR5 fluorescence intensity was
quantitated in the GC Tfh subset for the four different conditions,
and only in the absence of both IL-6 and IL-21 was a significant
reduction in CXCR5 protein observed (P=0.04; Figure 6G).
Collectively, these data demonstrate that optimal Tfh differenti-
ation requires cooperation between IL-6 and IL-21.
In order to determine whether the reduction in Tfh differen-
tiation that we observed in the combined absence of IL-6 and IL-
21 was specific to the Tfh subset, we characterized the frequency
Figure 6. IL-6 or IL-21 is required for optimal Tfh differentiation. (A–G) Splenocytes were analyzed 8 days following LCMV infection in
C57BL/6 (B6) or IL-21
2/2 mice 6 aIL6. (A) Follicular helper T (Tfh) cells (CXCR5
+SLAM
lo, boxed) gated on activated (CD44
hi) CD4 T cells. (B) Percentage
of Tfh differentiation (from gated Tfh population). **, P=0.0016. (C) Quantitation of DCXCR5 mean fluorescence intensity (MFI) gated on Tfh
(normalized against CD44
lo CD4 T cells). **, P=0.003. ***, P,0.0001. (D) Left, quantitation of Bcl6 protein DMFI in Tfh (normalized against CD44
lo CD4
T cells). ***, P=0.0009. Right, histogram overlay shows Bcl6 expression in a representative B6 vs. IL-21
2/2 + aIL-6 Tfh population (B6, black; IL-21
2/2 +
aIL-6, red; B6 stained with isotype mAb, gray). (E) FACS analysis of germinal center CD4 T (GC Tfh) cells (CXCR5
+GL7
+, boxed). Gated CD44
hi CD4 T
cells shown. (F) GC Tfh quantitation. **, P=0.003. (G) DCXCR5 MFI, gated on GC Tfh and normalized against CD44
lo CD4 T cells. *, P=0.0405. Flow
cytometric analysis of intracellular cytokine staining for IFNc production by CD4 T cells after 4 h stimulation with PMA and ionomycin in the presence
of brefeldin A. (H) Frequency of IFNc
+CD44
hi CD4 T cells. Data are representative of $2 independent experiments; n=5–6 mice per group. MFI, mean
fluorescence intensity; ns, not significant.
doi:10.1371/journal.pone.0017739.g006
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[24,27,49], the lack of either IL-6 or IL-21 did not lead to any
reduction in IFNc
+ CD4 T cells, and we did not observe any loss
in the combined absence of both IL-6 and IL-21 (Figure 6H).
Although both cytokines are reported to negatively regulate IFNc
production [50,51], IL-21, more so than IL-6, appeared to
suppress the generation of non-Tfh antigen specific cells
(Figure 6H). Thus, our data suggests that the observed reduction
in Tfh in the absence of both IL-6 and IL-21 is specific to the Tfh
subset, and not due to a general suppression of antiviral CD4 T
cell responses.
Discussion
This is the first study to characterize cooperative functions for
IL-6 and IL-21 in Tfh differentiation and generation of B cell
immunity in vivo. IL-21 is known to be a major factor for
generation of sustained high affinity antibody responses in vivo
[25,26,39,46], consistent with IL-21 being the most potent known
inducer of plasma cell differentiation in vitro [48,52,53]. In
addition, IL-21R
2/2 and IL-21
2/2 mice exhibit germinal center
defects [22,44]. B cells expressing IL-21R and IL-21 were recently
shown to be important, in a B cell intrinsic manner, for optimal
proliferation of germinal center B cells [25,26]. Given that IL-6
and IL-21 share signaling pathways, and B cells express receptors
for both cytokines, we characterized B cell responses in mice
deficient for both IL-6 and IL-21 signaling.
The combined loss of both IL-6 and IL-21 almost completely
abrogated early virus-specific antibody production, indicating that
both cytokines cooperate to drive plasma cell responses (Figure 4).
IL-6 is a potent growth and maturation factor for developing
human plasma cells, both in vitro [54,55] and in vivo (including
pathogenic conditions [56,57,58,59]), but has minimal capacity to
directly induce plasma cell differentiation [54,60]. IL-6 enhances
the proliferation and survival of plasmablasts [54], B cells that
have already initiated the process of differentiating to plasma cells.
IL-6 also enhances the antibody secretion of those plasmablasts
[61]. Given that IL-6 signals through STAT3 in B cells and can
upregulate Blimp-1 expression [47,61], it is likely that IL-6
enhances immunoglobulin production of developing plasma cells
by maximizing Blimp-1 expression [61], which consequently
upregulates the massive secretory apparatus program of plasma
cells [47,62]. Interestingly, this role of IL-6 appears to be primarily
important early during a T-dependent immune response, as
antibody levels in the absence of IL-6 are normal by day 15 post-
infection [27]. This indicates that IL-6 is predominantly involved
in enhancing the maturation of T-dependent extrafollicular
plasma cells, prior to germinal center formation. Germinal center
formation is detectable at day 6 after acute LCMV infection, with
a large germinal center response present by day 8 post-infection.
The reduction in plasma cell numbers at day 8 in the absence of
IL-21 is most likely a reflection of the critical role of IL-21 in
driving plasma cell differentiation from germinal center B cells
(Figure 4B–C) [25,26,46]. IL-21 is a potent STAT3-dependent
inducer of Blimp-1 [40,47,48]. Thus the combined absence of IL-6
and IL-21 through 8 days post-infection results in a predominantly
IL-6 dependent loss of antibody production by the extrafollicular
plasma cells, and the absence of germinal center derived plasma
cells (IL-21 dependent), resulting in a near complete abrogation of
the serum antibody response to the viral infection.
We observed no early role for IL-6 in germinal center B cell
differentiation. The combined loss of both IL-21 and IL-6 had no
effect on GC B cell frequency beyond IL-21 deficiency alone
(Figure 5). Therefore, enhancement of germinal center B cell
proliferation is a unique attribute of IL-21. IL-6 may function
solely to enhance plasma cell maturation and antibody production.
Stromal cells in the B cell follicle, most likely follicular dendritic
cells, are capable of producing IL-6 [3,63,64]. However, IL-21 is
not the sole factor involved in GC B cell differentiation and
proliferation, as the germinal center response in the absence of IL-
21 was approximately half of wild type levels. IL-21R
2/2IL-4
2/2
mice exhibit a more severe loss of GC B cells than IL-21R
2/2
mice [44]. In addition to being a class switch factor, IL-4 enhances
B cell survival and proliferation [65,66]. Interestingly, IL-4 is
specifically upregulated in GC Tfh cells [17,67,68,69]. IL-4
secretion by GC Tfh is controlled by a different pathway than Th2
produced IL-4 [17]. It is conceivable that numerous soluble factors
can contribute significantly to germinal center B cell differentiation
and maintenance, given that affinity maturation and the
generation of germinal center derived plasma cells and memory
B cells is a central process of adaptive immunity. This is an area
worthy of extensive further investigation.
The combined absence of IL-6 and IL-21 led to a significant
reduction in Tfh frequency, with a corresponding reduction in
both CXCR5 and Bcl6 protein expression (Figure 6). In contrast,
no effect on Tfh differentiation was observed with the loss of IL-6
alone or IL-21 alone (Figure 6), suggesting that these cytokines
share redundant functions in vivo in regulating development of
Tfh in response to a viral infection. Exactly how IL-6 and IL-21
regulate Tfh development is still unclear. The reduction in Bcl6
protein levels in Tfh that developed in the combined absence of
IL-6 and IL-21 indicates these cytokines have a direct effect on the
Bcl6 gene in CD4 T cells in vivo. This is consistent with in vitro
data on the effects of IL-6 and IL-21 (Figure 3 and ref. [5]).
Tfh development and function is intimately linked with B cells
through their co-localization and selective upregulation of
complementary surface molecules that enhance T-B interactions
[4,8,17,20,70], and Tfh are not normally observed in the absence
of antigen-specific interactions with B cells [4,12,68,71]. Consti-
tutive expression of Bcl6 in CD4 T cells can overcome the
requirement for cognate T-B interactions during Tfh develop-
ment, indicating that B cells provide a signal inducing or
enhancing Bcl6 expression in CD4 T cells [4,20]. In this context,
it is interesting to note that Tfh development was largely
unaffected in IL-21
2/2 mice, which had reduced germinal center
B cells compared to wildtype mice (Figure 6). T cell help is
commonly the limiting factor in germinal center B cell numbers
[72], and IL-21 production is an important part of the T cell help.
While T cell help is limiting for germinal center B cell numbers,
the converse is not the case here. Tfh depend on the presence of
cognate B cells [4], but the IL-21
2/2 data here leads to the
reasonable assumption that cognate B cells are required but not
limiting for Tfh numbers at the peak of the antiviral CD4 T cell
response. Furthermore, since germinal center development was
equivalent in IL-21
2/2 mice and IL-21
2/2 mice treated with anti-
IL-6 neutralizing mAb, the reduced Tfh numbers in the combined
absence of both cytokines is interpreted as a direct effect on the
CD4 T cells, not via germinal center B cells.
Curiously, IL-21 [40] and IL-6 (Figure 3) both induce Blimp-1
in purified naive CD4 T cells in vitro. Blimp-1 blocks Tfh
differentiation [4]. This indicates that an additional signaling
pathway, independent of IL-6 or IL-21, must be activated to
prevent Blimp-1 expression and allow for Bcl6 expression to
predominate. Furthermore, while IL-6 and IL-21 clearly partic-
ipate in generation of the Tfh subset, substantial Tfh differenti-
ation was observed in the absence of both cytokines. This indicates
Tfh differentiation pathways exist that are IL-6 and IL-21
independent.
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JAK-STAT pathway. Both IL-6 and IL-21 signal predominantly
through STAT3 [28,31,40,43,73], although STAT1 and STAT5
are also activated in the presence of these cytokines [74]. It has
been reported that STAT3
fl/fl CD4-Cre
+ mice exhibit reduced
Tfh frequencies, though only a single mouse was shown [7]. In B
cells, the role of STAT3 is complex. STAT3 is important in B cells
for the induction of Blimp1 [40] and plasma cell differentiation
[48,75]. However, STAT3 can also induce Bcl6 in B cells [46].
Nevertheless, STAT3 is not required for Bcl6 expression in B cells
and germinal center formation, as mice or humans with STAT3
deficiency have germinal centers [46,75]. IL-6 and IL-21 induce
both Bcl6 and Blimp-1 in CD4 T cells. STAT3
fl/fl CD4-Cre
+ CD4
T cells fail to upregulate Blimp-1 upon TCR stimulation in the
presence of IL-21 [40]. These findings indicate that the roles of
STAT3 in both CD4 T cells and B cells may be complex, and may
not directly correlate with the functions of IL-6 and IL-21.
In the context of an acute viral infection, we observed complete
redundancy in the roles for IL-6 and IL-21 in Tfh development at
the peak of the effector CD4 T cell response. Redundancies in
signaling pathways and cellular differentiation processes are
frequently associated with crucial biological processes. Therefore,
it is not surprising that there is a high degree of overlap in signals
needed for generation of the CD4 T cells required for B cell help,
given that antibody responses are essential for combating a vast
array of infectious diseases. In addition, redundancies in pathways
also make it substantially more difficult for pathogens to evade the
immune system. IL-6 and IL-21 are largely produced by different
cell types (DCs and non-hematopoeitic cells vs. CD4 T cells) and
are dependent upon the stimuli encountered. Therefore, it may be
expected that, of IL-6 or IL-21, one likely has a more prominent
role than the other in the context of different antigenic insults at
different sites under different conditions, or if a pathogen
suppresses induction of one of these cytokines.
While our data support a collaborative role for IL-6 and IL-21
in Tfh differentiation, these cytokines are not sufficient for
instruction of Tfh differentiation (Figure 3). All of the other
known CD4 T cell subsets can be derived from purified naı ¨ve CD4
T cells cultured in the presence of cytokine(s) plus TCR
stimulation [76], and these polarized cells express high levels of
their signature cytokine as well as upregulation of their associated
master regulator transcription factor. However, here we have
demonstrated that induction of high IL-21 from polarized naive
purified CD4 T cell cultures (Figure 2) does not equal Tfh
differentiation, as characterized by increased protein expression of
both Bcl6 and CXCR5 (Figure 3). IL-6 or IL-21 are therefore
insufficient to drive Tfh differentiation in vitro. Alternatively, Tfh
may require an additional cytokine for their induction, in keeping
with the mechanism of other CD4 T cell differentiation pathways.
This observation does not contradict earlier studies in which in
vitro Tfh or pre-Tfh were reported [5,77]. Those studies utilized
naı ¨ve CD4 T cells cultured with irradiated splenocytes supple-
mented with either IL-6 or IL-21. We interpret all of these results
as supporting the conclusion that IL-6 and IL-21 are insufficient,
but they can interact with additional factors present in vivo, or in
more complex cell mixtures in vitro, to drive Tfh differentiation.
Controversy has surrounded the role of IL-21 and IL-6 in Tfh
differentiation, as the absence of either cytokine alone has often led
to conflicting reports of Tfh development in vivo [7,22,24,25,
26,27]. This study is the first to characterize the effects on Tfh
differentiation and B cell development in the combined absence of
both IL-6 and IL-21. We demonstrate that these cytokines share
cooperative functions in the generation of humoral immunity in
vivo. Tfh differentiation is a complex process with multiple
overlapping and redundant signals promoting the development of
this subset. These results help clarify the path to understanding the
signals necessary and sufficient for Tfh differentiation.
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